What is the relative importance of cost-effectiveness information? Results from a Discrete Choice Experiment among Swedish medical decision makers. Sandra Erntoft (PhD) Project Manager The Swedish Institute for Health Economics (IHE) P.O. Box 2127, 220 02 Lund +46 46 32 91 21 www.ihe.se 2 Background • Previous research suggests that the relative importance of cost-effectiveness information varies between reimbursement-, formulary-, and prescribing - decisions. • Little research has, however, investigated all three priority setting context simultanously… • …and often used different methodologies and methods to investigate this question. • Does the potential differences in the importance influence the threshold values of cost per QALY? 3 Purpose • • • • The purpose of the experiment was to investigate the relative importance of cost-effectiveness information (cost/QALY) compared with four other criteria; health status, expected size of medical effect, type of medical effect, budget impact, AND which values of a QALY are acceptable to the TLV, formulary committees and prescribing physicians? 4 Methods • A sample of 996 questionnaires (TLV 53; formulary committee members 362; physicians 581). • Previous study (Johnson & Backhouse 2006) and focus group consisting of 5 senior experts). • 5 criteria – three reflecting need and two economics - 3 levels each. • Two questions; A (ranking – ”forced choice”) and B (decision) in order to identify threshold values. • 243 possible combinations or approx. 29 000 questions – main effects only + division into three blocks. • Orthogonal design – iterative computer search algorithms in order to maximize D-efficiency. • Conditional logit models. 5 Example of a D C question directed towards the TLV Criteria Treatment A Treatment B The average health status in patient population High degree of pain/discomfort Low degree of pain/discomfort Type of medical effect Increased QoL Life-sustainment Expected size of medical effect (effectiveness) Avoid loss of 1 QALY Avoid loss of 0.2 QALY Cost per QALY 102 000 € 28 000 € Budget Impact 280 000 € per 100 000 inhabitants 18 600 € per 100 000 inhabitants A) Which treatment is better? (A is better, B is better) B) Which treatment do You think TLV should reimburse? (A, B, both A and B, neither A or B) 6 Formulas A question (ranking): Uij=αpain*PAIN+αtype_eff*TYPE_EFF+αQALYgain*QALY_GAIN+αcost/QAL Y*COST_QALY+αbudg.imp.*BUDG_IMP B question (decision): Vij=βpain*PAIN+βtype eff* TYPE_EFF+ β QALYgain*QALY_GAIN+ β cost/QALY*COST_QALY+ β budg.imp.*BUDG_IMP 7 Descriptive statistics TLV Form. Com. Physicians 52,2 54,9 47,3 78 62 43 25 50 0 0 25 86 0 0 2 12 83 N/a N/a N/a 17 HE education (% yes) 58 35 12 Budget/ Operational responsibility (% yes) N/a 22 23 Age (mean) Sex ( % males) Education: Physician Economist Lawyer Pharmacist Other/no answer Response rate: 21 % 8 Result 1: Relative importance when ranking pharmaceutical treatments 3.5 3 2.4 2.4 2.5 2.1 2 1.8 1.4 1.5 1 1.8 1.1 1.0 1.0 1.0 0.5 0.9 0.3 0.3 0.4 0.5 0 Cost/QALY Budg. Imp. Type of med. eff. Pain QALY gain TLV Form. Com. Prescribers 9 Result 2: Relative importance when making a decision 1.6 1.4 1.4 1.2 1.2 1 1.1 1.0 1.0 1.0 0.9 0.8 0.8 0.7 0.6 0.6 0.5 0.4 0.2 0.2 0.2 0.4 0.3 0 Cost/QALY QALY gain Budg. Imp. Type med. eff. Pain TLV Form. Com Physicians 10 Result 3: Cost-effectiveness threshold values • 41 cases of statistically significant differences between decision makers. • In 28 cases the cost-effectiveness threshold values were lower rated by the TLV, than by formulary committee members and prescribing physicians. Cost per QALY • TLV: Lowest 43 600 € ; Highest 107 500 €. • Formulary committees: Lowest - 5 400 € ; Highest 304 200 € • Physicians: Lowest 4 900 € ; Highest 240 800 €. 1€ = 10,75 SEK (December 2009) ~ 1.3 U.S. $ 11 Discussion • Cost-effectiveness information more important in reimbursement- than in formulary- and prescribingdecisions. Confirms results from previous research. • Threshold values are lower in reimbursment- than in formulary- and prescribing decisions. Can this be explained by differences in educational backgrounds? • Higher threshold values in Sweden than in for instance the Netherlands. • Willingness to reimburse (WTR) rather than willingness to pay (WTP) – social utilities rather than individual utilities. • The WTR is based on the relative value of the public program (the treatment option rejected) foregone. 12 Conclusions • Both the relative importance of cost-effectiveness information and the threshold values of the cost/QALY varies between decision makers at national, regional and local level. • The relatively high threshold values among formulary committee members and prescribing physicians may be a sign of a lack of social learning regarding the necessity of setting priorities due to scarce resources…. • …or a result of the fact that priority setting is more difficult the closer the decision maker is to the patient. 13 Thank you for your attention! Sandra Erntoft Email: Sandra.Erntoft@ihe.se Phone: +46 46 32 91 21